Arzerra ofatumumab regulatory update

FDA approved an sBLA from Novartis for Arzerra ofatumumab in combination with fludarabine and cyclophosphamide to treat relapsed chronic lymphocytic leukemia (CLL). Arzerra is approved in combination ...